(Q40035245)

16 September 2017

title

Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel (English)

1 reference

16 September 2017

7

Kazunari Akiyoshi

1 reference

16 September 2017

11

Lloyd J Old

1 reference

16 September 2017

2

Shigehisa Kitano

1 reference

16 September 2017

Shinichi Kageyama

1

1 reference

16 September 2017

Michiko Hirayama

3

1 reference

16 September 2017

Yasuhiro Nagata

4

1 reference

16 September 2017

Hiroshi Imai

5

1 reference

16 September 2017

Taizo Shiraishi

6

1 reference

16 September 2017

Andrew M Scott

8

1 reference

16 September 2017

Roger Murphy

9

1 reference

16 September 2017

Eric W Hoffman

10

1 reference

16 September 2017

Naoyuki Katayama

12

1 reference

16 September 2017

Hiroshi Shiku

13

1 reference

16 September 2017

publication date

15 December 2007

1 reference

16 September 2017

1 reference

16 September 2017

volume

99

1 reference

16 September 2017

issue

3

1 reference

16 September 2017

page(s)

601-607

1 reference

Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00705.X

A survey of the humoral immune response of cancer patients to a panel of human tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00705.X

Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00705.X

HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00705.X

Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00705.X

IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00705.X

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00705.X

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00705.X

GM-CSF-secreting melanoma vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00705.X

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00705.X

Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00705.X

10.1111/J.1349-7006.2007.00705.X

21 January 2018

Identifiers

DOI

1 reference

16 September 2017

1 reference